Document:

Exhibit 10.14

                             TERMINATION AGREEMENT

         This Termination Agreement (the "Agreement") is made and entered into
this 28th day of February, 2002, by and between The University of Texas M.D.
Anderson Cancer Center ("UTMDACC"), a component institution of The University of
Texas System, and B. Twelve, Inc. ("BTI").

         WHEREAS, UTMCACC and BTI entered into a Sponsored Laboratory Study
Agreement dated August 31, 1999, which was amended by an Amendment No. 1 to
Research Agreement dated November 20, 2000 (the "SLS Agreement");

         WHEREAS, the SLS Agreement provided for BTI to sponsor a study (the
"Study") undertaken by UTMDACC and Dr. Robert Newman (the "Principal
Investigator");

         WHEREAS, BTI is in default of its financial obligations to UTMDACC
under the SLS Agreement; and

         WHEREAS, the parties desire to terminate the SLS Agreement;

         NOW THEREFORE, for good and valuable consideration, including in
consideration of the mutual benefits, terms, and conditions expressed herein,
the parties hereby agree as follows:

1.       The SLS Agreeement is hereby terminated, and as a consequence of which,
         all terms and provisions of the SLS Agreement are hereafter null, void,
         and unenforceable. Neither party shall hereafter owe any duty or
         obligation to the other under the SLS Agreement.

2.       The parties hereby release, waive, and relinquish all rights, claims
         and benefits under the SLS Agreement.

3.       UTMDACC and the Principal Investigator shall have the unrestricted
         right to continue and pursue the Study in any manner and with any other
         party or sponsor and without any obligation to BTI.

4.       This Agreement shall be governed by the laws of the State of Texas
         without regard to its conflicts of law provisions.

5.       This Agreement may be signed in multiple counterparts, each of which
         shall be deemed an original, but all of which together shall be one and
         the same instrument.

<PAGE>

         NOW THEREFORE, having agreed to the terms and provisions set forth
herein, the parties have caused this Agreement to be signed as of the date
written above by the duly authorized representatives below.

THE UNIVERSITY OF TEXAS                                B. TWELVE, INC.
M.D. ANDERSON CANCER CENTER

By: /s/Leonard A. Zwelling                             By: /s/Jean-Luc Berger
-------------------------------------                  -------------------------
Leonard A. Zwelling, M.D., M.B.A.                      Jean-Luc Berger, Ph.D.
Vice President for Research Administration             President & C.E.O.

Date: 3/14/02                                          Date: February 28, 2002
-------------------------------------                  -------------------------
Reviewed and approved
for signature:(illegible)
              -----------------------

Approved for signature:

/s/Robert A. Newman
------------------------------
Robert A. Newman, Ph.D.Exhibit 10.15

                         COLLABORTIVE RESEARCH AGREEMENT

         This Agreement, made and effective as of November 11, 1999, ("the
Effective Date") is by and between:

         NEW YORK UNIVERSITY (hereinafter "NYU"), a corporation organized and
existing under the laws of the State of New York and having a place of business
at 70 Washington Square South, New York, New York 10012, USA

                                       AND
                                       ---

         B TWELVE, INC. (hereinafter "CORPORATION"), a corporation organized and
existing under the laws of the State of Florida having its principal office at
3303-130 Adelaide Street West, Toronto, Ontario, Canada M5H 3P5.

                                    RECITALS
                                    --------

         WHEREAS, Dr. Stephen R. Wilson of NYU (hereinafter "the NYU Scientist")
has expertise and performs research in organic chemistry drug design and
synthesis;

         WHEREAS, NYU is willing to perform the NYU Research Project (as
hereinafter defined);

         WHEREAS, CORPORATION is prepared to sponsor the NYU Research Project;

         WHEREAS, subject to the terms and conditions hereinafter set forth NYU
is willing to grant to CORPORATION and CORPORATION is willing to accept from NYU
an option to acquire a license to use and practice the Research Technology (as
hereinafter defined);

         NOW, THEREFORE, in consideration of the mutualpromises and agreements
contained herein, the parties hereto hereby agree as follows:

                                        1
<PAGE>

1.       Definitions.
         ------------

         Whenever used in this Agreement, the following terms shall have the
         following meanings:

         a.  "Corporation Entity" shall mean any company or other legal entity
             which controls, or is controlled by, or is under common control
             with, CORPORATION; control means the holding of more than
             twenty-five and one tenth percent (25.1%) or more of

             i)   the capital and/or

             ii)  the voting rights and/or

             iii) the right to elect or appoint directors.

         b.  "Field" shall mean design and chemical synthesis of cyanocobalamin
             (vitamin B12) derivatives.

         c.  "NYU Know-How" shall mean any information and materials including,
             but not limited to, pharmaceutical, chemical, biological and
             biochemical products,, information and trade secrets, know-how,
             technical and non-technical data, materials, methods and processes
             and any drawings, plans diagrams, specifications and/or other
             document containing such information, discovered, developed or
             acquired by, or on behalf of students or employees of NYU during
             the term and in the course of the performance of the NYU Research
             Project;

         d.  "NYU Patents" shall mean all United States and foreign patents and
             patent applications, and any divisions, continuations, in whole or
             in part, reissues, renewals and extensions thereof, and pending
             applications therefore which claim inventions that are made by
             students or employees of NYU during the term and in the course of
             the performance of the NYU Research Project.

         e.  "NYU Research Project" shall mean the investigations during the
             Research Period (as hereinafter defined) into the Field under the
             supervision of the NYU Scientist in

                                       2
<PAGE>

             accordance with the research program, described in annexed Appendix
             I, which forms an integral part hereof.

         f.  "Option Period" means the period from the Effective Date (as
             defined below) to the date 180 days after the end of the Research
             Period.

         g.  "Research Period" shall mean the two-year period commencing on the
             Effective Date hereof and any extension thereof as to which NYU and
             CORPORATION shall mutually agree in writing.

         h.  "Research Technology" shall mean all NYU Patents and NYU Know-How.

2.       Effective Date.
         --------------

         This Agreement shall be effective as of the Effective Date and shall
         remain in full force and effect until it expires or is terminated in
         accordance with Section 9 hereof.

3.       Performance of the NYU Research Project.
         ---------------------------------------

         a.  In consideration of the sums to be paid to NYU as set forth in
             Section 4, below, NYU undertakes to perform the NYU Research
             Project under the supervision of the NYU Scientists during the
             Research Period. If, during the Research Period the NYU Scientist
             shall cease to supervise the NYU Research Project, then NYU shall
             endeavor to find from among the scientists of NYU a scientist or
             scientists acceptable to CORPORATION to continue the supervision of
             the NYU Research Project in place of the NYU Scientist. Nothing
             herein contained shall be deemed to impost an obligation on NYU to
             find a replacement for the NYU Scientist.

         b.  Nothing contained in this Agreement shall be construed as a
             warranty on the part of NYU that any results will be achieved by
             the NYU Research Project, or that the Research Technology and/or
             any other results achieved by the NYU Research Project, if any, are
             or will be commercially exploitable and furthermore, NYU makes no
             warranties whatsoever as to the commercial or scientific value of
             the

                                       3
<PAGE>

             Research Technology and/or as to any results which may be achieved
             in the NYU Research Project.

         c.  The NYU Scientist shall prepare semi-annual reports within thirty
             (30) days after the end of each six month period after the
             Effective Date, summarizing the results of the work conducted on
             the NYU Research Project during such six-month period. Within sixty
             (60) days after the end of the Research Period, the NYU Scientist
             shall prepare a written report summarizing the results of the work
             conducted on the NYU Research Project.

         d.  At mutually agreed upon times, representatives of CORPORATION may
             meet with the NYU Scientist to review and discuss the conduct and
             results of the NYU Research Project.

         e.  CORPORATION shall grant to NYU a non-exclusive research license
             under CORPORATION patents identified in Appendix II attached
             herein, for the purpose of the performance of the NYU Research
             Project.

         f.  NYU will have full authority and responsibility for the NYU
             Research Project. All students and employees of NYU who work on the
             NYU Research Project will do so as employees or students of NYU,
             and not as employees of CORPORATION.

4.       Funding of the NYU Research Project.
         -----------------------------------

         a.  As compensation to NYU for work to be performed on the NYU Research
             Project during the Research Period, subject to any earlier
             termination of the Research Project pursuant to Section 3.a.
             hereof, CORPORATION will pay NYU the total sum of U.S. $373,250,
             payable according to the following schedule: for the first year of
             the Research Period a total sum of U.S. $222,560 payable in four
             (4) equal consecutive quarterly installments of U.S. $555,640 each,
             commencing upon the Effective Date and on the first business day of
             the 3rd, 6th, and 9th month commencing after the Effective Date,
             and for the second year of the Research

                                       4
<PAGE>

             Period a total sum of U.S. $150,690 payable in four (4) equal
             consecutive quarterly installments of U.S. $37,672.50 each,
             commencing upon the first business day of the 12th, 15th, 18th and
             21st month commencing after the Effective Date.

         b.  Nothing in this Agreement shall be interpreted to prohibit NYU (or
             the NYU Scientist) from obtaining additional financing or research
             grants for the NYU Research Project from government agencies, which
             grants or financing may render all or part of the NYU Research
             Project and the results thereof subject to the patent rights of the
             U.S. Government and its agencies, as set forth in Title 35 U.S.C.
             ss.200 et seq.

5.       Title.
         ------

         a.  All right, title and interest, in and to the Research Technology,
             and to any other results achieved by the NYU Research Project, and
             in and to any drawings, plans, diagrams, specifications and other
             documents containing any of the Research Technology shall vest
             solely in NYU.

         b.  Subject to the rights granted to CORPORATION pursuant to Section 6,
             hereof, for so long as the NYU Scientists is employed by NYU, any
             and all inventions made by the NYU Scientist and relating to the
             Field shall be owned solely by NYU.

6.       Option to Negotiate the New Agreement
         -------------------------------------

         a.  For the term of the Option Period and subject to the satisfaction
             by CORPORATION of the conditions set forth in 6.b. hereof, NYU
             hereby grants to CORPORATION the exclusive option at any time
             during the Option Period to negotiate a new agreement with respect
             to an exclusive option at any time during the Option Period to
             negotiate a new agreement with respect to an exclusive worldwide
             license to use and practice the Research Technology (the "New
             Agreement").

         b.  CORPORATION may exercise the option set forth above by providing
             NYU with written notice that CORPORATION is prepared to negotiate
             the New Agreement.

                                       5
<PAGE>

         c.  CORPORATION shall have no right to undertake any commercial use
             (including trials in humans) of the Research Technology or the
             manufacture, or sale of a product based on the Research Technology,
             unless and until CORPORATION and NYU execute the New Agreement
             pursuant to Section 6, hereof.

         d.  NYU shall not, during the Option Period, grant to any third party
             any rights, or take any action inconsistent with, the rights
             granted to CORPORATION under this Agreement.

         e.  The New Agreement that may be negotiated for the aforesaid Research
             Technology shall include reasonable and customary terms and
             conditions (including, but not limited to reasonable royalties)
             with respect to university-industry agreements.

7.       Patents and Patent Applications.
         -------------------------------

         a.  NYU will promptly disclose to CORPORATION in writing any inventions
             which constitute potential NYU Patents.

         b.  CORPORATION shall maintain all disclosures in confidence and shall
             not deliver or divulge them to any person or entity.

         c.  At the initiative of CORPORATION or NYU, the parties shall consult
             with each other regarding the prosecution of all patent
             applications in respect of any inventions pertaining to the
             Research Technology, including but without limitation, the timing
             of the filing of such applications, the jurisdiction within which
             foreign counterparts of such applications should be filed and other
             details pertaining to the procurement and maintenance of patent
             rights.

         d.  Notwithstanding anything to the contrary in Section 7.c. hereof,
             NYU shall determine the patentability of any invention pertaining
             to the Research Technology, and the desirability of filing or
             prosecuting patient applications thereon.

         e.  All patent applications and patents pertaining to NYU Patents shall
             be filed, prosecuted and maintained by NYU through patent counsel
             selected by NYU, after

                                       6
<PAGE>

             consultation with CORPORATION, at the expense of CORPORATION.
             Against the submission of invoices, CORPORATION shall reimburse NYU
             for all costs and fees incurred by NYU in connection with the
             filing, maintenance, prosecution and protection of the NYU Patents.

         f.  NYU and CORPORATION shall assist, and cause their respective
             employees and consultants to assist each other, in assembling
             inventorship information and data for the filing and prosecution of
             patent applications on inventions pertaining to the Research
             Technology. The scope, content and inventorship of such patent
             applications and the prosecution thereof, will be determined solely
             by NYU after consultation with CORPORATION as set forth in Section
             7.c. hereof.

         g.  Nothing herein contained shall be deemed to be a warrant by NYU
             that NYU can or will be able to obtain any patent or patents on any
             patent application or applications in the NYU Patents or any
             portion thereof, or that any of the NYU Patents will afford
             adequate or commercially worthwhile protection.

8.       Publication.
         ------------

         a.  Prior to submission for publication of a manuscript describing the
             results of any aspect of the NYU Research Project, NYU shall send
             CORPORATION a copy of the manuscript to be submitted, and shall
             allow CORPORATION thirty (30) days from the date of such mailing to
             determine whether the manuscript contains such subject matter for
             which patent protection should be sought prior to publication of
             such manuscript, for the purpose of protecting an invention made by
             the NYU Scientist during the course and in the performance of the
             NYU Research Project. Should CORPORATION believe the subject matter
             of the 30-day period from the mailing date of such manuscripts to
             CORPORATION by NYU, CORPORATION shall give written notification to
             NYU of:

             i)  its determination that such manuscript contains patentable
                 subject matter for which patent protection should be sought;
                 and

                                       7
<PAGE>

             ii) the countries in which such patent protection should be sought.

         b.  After the expiration of such 30-day period from the date of mailing
             such manuscript to CORPORATION, unless NYU has received the written
             notice specified above from CORPORATION, NYU shall be free to
             submit such manuscript for publication to publish the disclosed
             research results in any manner consistent with academic standards.

         c.  Upon receipt of such written notice from CORPORATION, NYU will
             thereafter delay submission of the manuscript for an additional
             period of up to sixty (60) days to permit the preparation and
             filing in accordance with Section 8, hereof of a U.S. patent
             application by NYU on the subject matter to be disclosed in such
             manuscript. After expiration of such 60-day period, or the filing
             of a patent application on each such invention, whichever shall
             occur first, NYU shall be free to submit the manuscript and to
             publish the disclosed results.

9.       Expiry and Termination.
         ----------------------

         a.  Unless earlier terminated pursuant to this Section 9.b. or 9.c.
             below, this Research Agreement will terminate upon the expiration
             of the Option Period. The provisions of Sections 9, 12 and 15
             hereof shall survive and remain in full force and effect after any
             expiration, cancellation or termination of this Agreement,
             including early termination as set forth below.

         b.  At any time prior to expiration of this Agreement pursuant to
             Section 9.a. hereof, any party may terminate this Agreement for
             cause, as "cause" is described below, by giving written notice to
             the other party. Cause for termination by one party of this
             Agreement shall be deemed to exist if the other party materially
             breaches or defaults in the performance or observance of any of the
             provisions of this Agreement and such breach or default is not
             cured within sixty (60) days after receipt of written notice
             thereof from the non-breaching party.

                                       8
<PAGE>

         c.  Any party to this Agreement may, upon giving notice of termination,
             immediately terminate this Agreement upon receipt of notice that
             any party has become insolvent or has suspended business or has
             filed a voluntary petition or an answer admitting the jurisdiction
             of the U.S. Bankruptcy Court in the material allegations of, or has
             consented to, an involuntary petition purporting to be pursuant to
             any reorganization or insolvency law of any jurisdiction, or has
             made an assignment for the benefit of creditors or has applied for
             or consented to the appointment of a receiver or trustee for a
             substantial part of its property.

         d.  Any amount payable hereunder by one of the parties to the other,
             which has not been paid by the date on which such payment is due,
             shall bear interest from such date until the date on which such
             payment is made, at the rate of two percent (2%) per annum in
             excess of the prime rate prevailing at the Citibank, N.A., in New
             York, New York, during the period of arrears and such amount and
             the interest thereon may be set off against any amount due, whether
             in terms of this Agreement or otherwise howsoever, to the part in
             default by any non-defaulting party.

         e.  Termination of this Agreement shall not relieve the parties of any
             obligation to the other party incurred prior to such termination.

11.      No Assignment.
         -------------

         Neither CORPORATION not NYU shall have the right to assign, delegate or
         transfer at any time to any party, in whole or in part, any or all of
         the rights, duties and interest herein granted without first obtaining
         the written consent of the other to such assignment.

12.      Confidential Information
         ------------------------

         CORPORATION shall maintain any and all of the Research Technology in
         confidence and shall not release or disclose any tangible or intangible
         component thereof to any

                                       9
<PAGE>

         third party without first receiving the prior written consent of NYU to
         said release or disclosure. This obligation of confidentiality shall
         not apply to any component of the Research Technology which is part of
         the public domain prior to the Effective Date of this Agreement or
         which becomes a part of the public domain not due to some unauthorized
         act by or omission of CORPORATION after the Effective Date of this
         Agreement or which is disclosed to CORPORATION by a third party who has
         the right to make such disclosure.

13.      Representations and Warranties by CORPORATION.
         ---------------------------------------------

         CORPORATION hereby represents and warrants to NYU as follows:

         a.  CORPORATION is a corporation duly organized, validly existing and
             in good standing under the laws of the State of Florida.
             CORPORATION has been granted all requisite power and authority to
             carry on its business and to own and operate its properties and
             assets. The execution, delivery and performance of this Agreement
             have been duly authorized by the Board of Directors of CORPORATION;

         b.  There is no pending or, to CORPORATION's knowledge, threatened
             litigation involving CORPORATION which WOULD HAVE ANY EFFECT ON
             THIS agreement or on CORPORATION's ability to perform its
             obligations hereunder, and

         c.  There is no indenture, contract, or agreement to which CORPORATION
             is a party or by which CORPORATION is bound which prohibits or
             would prohibit the execution and delivery by CORPORATION of this
             Agreement or the performance or observance by CORPORATION of any
             term or condition of this Agreement.

14.      Representations and Warranties by NYU.
         -------------------------------------

         NYU hereby represents and warrants to CORPORATION as follows:

         a.  NYU is a corporation duly organized, validly existing and in good
             standing under the laws of the State of New York. NYU has been
             granted all requisite power and

                                       10
<PAGE>

             authority to carry on its business and to own and operate its
             properties and assets. The execution, delivery and performance of
             this Agreement have been duly aiuthorized by the Board of Trustees
             of NYU.

         b.  There is no pending or, to NYU's knowledge, threatened litigation
             involving NYU which would have any effect on this Agreement or on
             NYU's ability to perform its obligations hereunder; and

         c.  There is no indenture, contract or agreement to which NYU is a
             party or by which NYU is bound which prohibits or would prohibit
             the execution and delivery by NYU of this Agreement or the
             performance or observance by NYU of any term or condition of this
             Agreement.

15.      Use of Name.
         -----------

         Without the prior written consent of the other party, neither
         CORPORATION nor NYU shall use the name of the other party or any
         adaptation thereof or of any staff member, employee or student, of the
         other party.

             i)  in any product labeling, advertising, promotional or sales
                 literature;

             ii) in connection with any public offering or private placement
                 documentation pr prospectus or in conjunction with any
                 application for regulatory approval, unless disclosure is
                 otherwise required by law, in which case either party may make
                 factual statements concerning the Agreement or file copies of
                 the Agreement after providing the other party with an
                 opportunity to comment and reasonable time within which to do
                 so on such statement in draft

         Except as provided herein, neither NYU nor CORPORATION will issue
         public announcements about this Agreement or the status or existence of
         the NYU Research Project without prior written approval of the other
         party.

                                       11
<PAGE>

16.      Miscellaneous.
         -------------

         a.  In carrying out this Agreement the parties shall comply with all
             local, state and federal laws and regulations including but not
             limited to, the provisions of Title 35 United States Code ss.200 et
             seq. and 15 CFR ss.368 et seq.

         b.  If any provision of this Agreement is determined to be invalid or
             void, the remaining provisions shall remain in effect.

         c.  This Agreement shall be deemed to have been made in the State of
             New York and shall be governed and interpreted in all respects
             under the laws of the State of New York.

         d.  Any dispute arising under this Agreement shall be resolved in an
             action in the courts of New York State or the federal courts
             located in New York State, and the parties hereby consent to
             personal jurisdiction of such courts in any such action.

         e.  All payments or notices required or permitted to be given under
             this Agreement shall be given in writing and shall be effective
             when either personally delivered or deposited, postage prepaid, in
             the United States registered or certified mail, addressed as
             follows:

                    To NYU:           New York University School of Medicine
                                      550 First Avenue
                                      New York, NY 10016
                                      USA

                                      Attention: Isaac T. Kohlberg
                                      Vice Provost

                                       12
<PAGE>

                                      and

                                      Office of Legal Counsel
                                      New York University
                                      Bobst Library
                                      70 Washington Square South
                                      New York, NY 10012

                                      Attention: Kathy Schultz

                    To CORPORATION:   B Twelve, Inc.
                                      3303-130 Adelaide Street West
                                      Toronto, Ontario M5H 3P5
                                      CANADA

                                      Attention: Uri Sagman, M.D., F.R.C.P.(C)
                                      President and CEO

             Or such other address or addresses as either party may hereafter
             specify by written notice to the other. Such notices and
             communications shall be deemed effective on the date of delivery of
             fourteen (14) days after having been sent by registered or
             certified mail, whichever is earlier.

         f.  This Agreement (and the annexed Appendices) constitute the entire
             Agreement between the parties and no variation, modification or
             waiver of any of the terms or conditions hereof shall be deemed
             valid unless made in writing and signed by both parties hereto.
             This Agreement supersedes any and all prior agreements or
             understandings, whether oral or written, between CORPORATION and
             NYU.

                                       13
<PAGE>

         g.  No waiver by either party of any non-performance or violation by
             the other party of any of the covenants, obligations or agreements
             of such other party hereunder shall be deemed to be a waiver of any
             subsequent violation or non-performance of the same or any other
             covenants, agreement or obligation, nor shall forbearance by any
             party be deemed to be a waiver by such party of its rights or
             remedies with respect to such violation or non-performance.

         h.  The descriptive headings contained in this Agreement are included
             for convenience and reference only and shall not be held to expand,
             modify or aid in the interpretation, construction or meaning of
             this Agreement.

         i.  It is not the intent of the parties to create a partnership or
             joint venture or to assume partnership responsibility or liability.
             The obligations of the parties shall be limited to those set out
             herein and such obligations shall be several and not joint.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement
effective as of the date and year first above written.

                  NEW YORK UNIVERSITY

                  By: /s/ Isaac T. Kohlberg
                      ------------------------------------
                          Isaac T. Kohlberg

                  Title: Vice Provost
                  Date: 11/11/99

                  B TWELVE, INC.

                  By: /s/ Uri Sagman
                      -------------------------------------
                          Uri Sagman

                  Title: President
                  Date: Nov. 11, 1999

                                       14
<PAGE>

                                   APPENDIX I

                                  Research Plan

The goal of the proposal is to synthesize monomeric and dimeric vitamin B12
analogs based on known chemistry and provide those compounds to B Twelve, Inc
for testing. We plan to develop solid-phase combinatorial chemistry to
accelerate the discovery of more effective B12 analogs.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]